Codexis, Inc.

CDXS | $2.765 -4.66% 120K

(0.0% 1d) (-15.9% 1m) (-28.7% 1y) (0.0% 2d) (1.4% 3d) (3.2% 7d) (-5.82% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 194,389,562
http://www.codexis.com
Sec Filling | Patents | 161 employees

(US) Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

optical food

add to watch list Paper trade email alert is off

Press-releases

Codexis to Report First Quarter 2024 Financial Results on May 2
Published: 2024-04-18 (Crawled : 20:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| 3.2% | O: -1.42% H: 3.61% C: 2.17%
first report financial results

Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| -6.45% | O: 0.65% H: 2.24% C: -0.32%

Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| -22.04% | O: 5.65% H: 24.94% C: 18.32%
year financial results

Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
Published: 2024-02-26 (Crawled : 21:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| -9.38% | O: 6.56% H: 29.91% C: 21.7%
dna roche agreement

Codexis to Participate in TD Cowen 44th Annual Health Care Conference
Published: 2024-02-26 (Crawled : 13:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| -4.29% | O: -0.66% H: 6.98% C: 6.31%
conference health care

Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
Published: 2024-02-20 (Crawled : 13:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| -8.81% | O: -1.26% H: 1.91% C: -7.96%

Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
Published: 2024-02-14 (Crawled : 21:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| 2.84% | O: 1.77% H: 13.24% C: 12.89%
report year financial results

Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
Published: 2024-02-13 (Crawled : 21:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| 6.81% | O: 3.87% H: 2.1% C: 0.0%
million key deal

seqWell and Codexis to Unveil Engineered Transposase Enzyme for Genomics Applications at AGBT General Meeting
Published: 2024-02-01 (Crawled : 21:00) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| 5.07% | O: -2.9% H: 2.8% C: 1.49%
genomics meeting

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108
Published: 2023-12-27 (Crawled : 13:30) - globenewswire.com
CDXS | $2.765 -4.66% 120K

Process Industries

| -12.65% | O: 1.51% H: 4.15% C: 0.0%
cdx-7108 health agreement

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000905148-24-000032	4	2024-01-03	2024-01-01	Buy	A	314125	314125
0000905148-24-000032	4	2024-01-03	2024-01-01	Buy	A	52350	175791
0000905148-24-000031	4	2024-01-03	2024-01-01	Buy	A	314125	314125
0000905148-24-000031	4	2024-01-03	2024-01-01	Buy	A	52350	150452
0000905148-24-000030	4	2024-01-03	2024-01-01	Buy	A	314125	314125
0000905148-24-000030	4	2024-01-03	2024-01-01	Buy	A	52350	133770
0000905148-24-000029	4	2024-01-03	2024-01-01	Buy	A	860500	860500
0000905148-24-000029	4	2024-01-03	2024-01-01	Buy	A	143425	582303